Form 4: Rapport Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

David Bredt, Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock at an average price of $9.5602 under a pre-arranged 10b5-1 trading plan.

Summary

• David Bredt, the Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of the company's common stock on May 15, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• The shares were sold at a weighted average price of $9.5602, with individual transaction prices ranging from $9.19 to $9.79.
• Following the transaction, Bredt directly owns 452,142 shares of Rapport Therapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment, as the sale was conducted under a pre-arranged trading plan.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large or coincides with other negative news.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, particularly in the pharmaceutical and biotech industries.
• Executives often use pre-planned trading programs like Rule 10b5-1 plans to diversify their holdings or manage personal finances.
• The size of this transaction (8,500 shares) is relatively small compared to the total shares outstanding and the executive's remaining holdings (452,142 shares).
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives related to stock sales and option exercises.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

Rapport Therapeutics, David Bredt, insider trading, Form 4, share sale, 10b5-1 trading plan, RAPP, Chief Scientific Officer